Lung Ultrasound Guided Protocol for Fluid Management for the Critically Ill Patient: a Randomized Study (LUNG US ICU)

Lung Ultrasound Guided Fluid Management Protocol for the Critically Ill Patient: a Randomized Study

In the Intensive Care Unit (ICU) this bedside method of assessing lung congestion could be useful in a better management of the critically ill patients with a wide range of respiratory failure causes (Acute Respiratory Distress Syndrome, COPD, acute pulmonary edema, pneumonia etc.). Fluid management is a key issue in the ICU where patients are either hemodynamic unstable and/or mechanically ventilated. A randomized study is proposed where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.

Study Overview

• Status: Unknown
• Conditions: Critical Illness
• Intervention / Treatment: Other: Fluid management guided by BLS

Detailed Description

Inclusion criteria

- Age 18 or older admitted to the Intensive Care Unit

Exclusion criteria

• Due to LUS measurement limitation: patients with known persistent pleurisy, pulmonary fibrosis or pneumectomy;
• Unwillingness to participate in the study.

Active arm diuretic administration algorithm

• Intravenous diuretics will be used only to decrease the BLS to < 15;
• A stepped diuretic administration algorithm is provided below;
• Investigators may opt-out of the stepped diuretic administration algorithm if they feel it is in the best interests of the patient care;
• Intravenous diuretics can be decreased or temporarily discontinued if there is a decrease in blood pressure or an increase in creatinine that is felt to be due to a transient episode of intravascular volume depletion. After the patient has stabilized, if BLS ≥ 15, intravenous diuretics should be reinitiated until the patient's BLS is <15.

Active arm Initial BLS ≥ 15 Diuretic dose Previous Dose Suggested dose Furosemide (/day) Furosemide (/day) Hydrochlorothiazide (/day)

1. ≤ 80 mg 40 mg iv bolus + 5 mg/h 0
2. 81-160 mg 80 mg iv bolus + 10 mg/h 12.5 mg
3. 161-240 mg 80 mg iv bolus + 20 mg/h 25 mg
4. >240 mg 80 mg iv bolus + 30 mg/h 25 mg

At 24 hours Persistent BLS ≥ 15 Negative fluid balance > 1000 ml - reduce current diuretic regimen if desired Negative fluid balance < 1000 ml - maintain current diuretic regimen Positive fluid balance - advance to next step in table

Dialysis initiation AKI will be diagnosed based on changes in the serum creatinine, urine output, or both (according to the KDIGO recommendations). Creatinine measurements will be performed twice per day. Every patient will have a urinary catheter and urine output will be measured every hour.

Criteria for renal replacement therapy initiation:

Stage 3 AKI (urine output <0.3 mL/kg/h for ≥24 h and/or >3 fold increase in serum creatinine level compared with baseline or serum creatinine of ≥4 mg/dL with an acute increase of at least 0.5 mg/dL within 48 hours or

If any of the following absolute indications for RRT were present:

• Blood urea nitrogen level higher than 112 mg/dL;
• Serum potassium level higher than 6 mEq/L and/or with electrocardiography abnormalities;
• Urine production lower than 200 mL per 12 hours or anuria (according to the KDIGO recommendations);
• Organ edema in the presence of AKI resistant to diuretic treatment;
• A pH below 7.15 in the context of either pure metabolic acidosis (Paco2 below 35 mm Hg) or mixed acidosis (Paco2 of 50 mm Hg or more without the possibility of increasing alveolar ventilation)
• Acute pulmonary edema due to fluid overload responsible for severe hypoxemia requiring an oxygen flow rate greater than 5 liters per minute to maintain a Spo2 greater than 95% or requiring a Fio2 greater than 50% in patients receiving mechanical ventilation and despite diuretic therapy.

• Study Type: Interventional
• Enrollment (Anticipated): 10
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: covic adrian, prof; Phone Number: 1603 +40.232.301.600; Email: accovic@gmail.com
• Study Contact Backup: Name: mihai onofriescu, prof; Phone Number: 1603 +40.232.301.600; Email: onomihai@yahoo.com

Study Locations

• Romania
  • Iași, Romania
    • Recruiting
    • Regional Institute of Oncology, Iasi
    • Contact: Siriopol Ianis; Phone Number: +o746215967; Email: ianis.siriopol@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age 18 or older admitted to the Intensive Care Unit

Exclusion Criteria:

• known persistent pleurisy, pulmonary fibrosis or pneumectomy (due to lung ultrasonography limitations);
• unwillingness to participate in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: intervention group pulmonary congestion; in the intervention group pulmonary congestion, as assessed by the BLS will guide the diuretic and fluid management, with a target of below 15 BLS. Furthermore, in the active arm, in the patients who will require a renal replacement therapy (RRT), BLS will be used to further guide the dialysis fluid prescription.	Other: Fluid management guided by BLS; We propose a randomized study where in the interventional arm the fluid management (volume replacement, diuretics, use of vasopressors) will be guided using the BLS as a sign of pulmonary congestion.
No Intervention: Control group; control group the fluid management will not be LUS guided

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
28 days survival	all-cause mortality	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Intensive care unit hospitalization	hospitalization in ICU	28 days
Duration of hospitalization	hospitalization	28 days
Days on mechanical ventilation	Need for mechanical ventilatory support	28 days

Collaborators and Investigators

• Sponsor: Professor Adrian Covic

Publications and helpful links

General Publications

• Ciumanghel A, Siriopol I, Blaj M, Siriopol D, Gavrilovici C, Covic A. B-lines score on lung ultrasound as a direct measure of respiratory dysfunction in ICU patients with acute kidney injury. Int Urol Nephrol. 2018 Jan;50(1):113-119. doi: 10.1007/s11255-017-1730-8. Epub 2017 Oct 30.
• Rusu DM, Siriopol I, Grigoras I, Blaj M, Ciumanghel AI, Siriopol D, Nistor I, Onofriescu M, Sandu G, Cobzaru B, Scripcariu DV, Diaconu O, Covic AC. Lung Ultrasound Guided Fluid Management Protocol for the Critically Ill Patient: study protocol for a multi-centre randomized controlled trial. Trials. 2019 Apr 25;20(1):236. doi: 10.1186/s13063-019-3345-0.

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2017
• Primary Completion (Anticipated): October 1, 2019
• Study Completion (Anticipated): December 31, 2019

Study Registration Dates

• First Submitted: December 6, 2017
• First Submitted That Met QC Criteria: January 5, 2018
• First Posted (Actual): January 8, 2018

Study Record Updates

• Last Update Posted (Actual): February 26, 2019
• Last Update Submitted That Met QC Criteria: February 25, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Keywords: lung ultrasounds; fluid managements; critical care patients
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Critical Illness
• Other Study ID Numbers: PN-III-P4-ID-PCE-2016-0908

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No